Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.

Drugs
Monique P Curran

Abstract

Amlodipine/atorvastatin (Caduet) is a single-tablet, fixed-dose combination of the dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase inhibitor atorvastatin. The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets. In well controlled clinical trials in patients with hypertension and dyslipidaemia, once-daily amlodipine and atorvastatin (administered as the single-tablet, fixed-dose combination or coadministered as two separate tablets) effectively reduced systolic BP (SBP) and low-density lipoprotein cholesterol (LDL-C) levels, and enabled more patients to achieve BP and LDL-C goals than single-agent or placebo therapy. There was no modification of the effect of amlodipine on SBP when administered in combination with atorvastatin and there was no modification of the effect of atorvastatin on LDL-C when administered in combination with amlodipine. In noncomparative, titration-to-goal, open-label 'real-world' trials, the single-tablet, fixed-dose combination of amlodipine/atorvastatin enabled patients with hypertension and dyslipidaemi...Continue Reading

References

Nov 1, 1981·The Journal of Clinical Investigation·P D Henry, K I Bentley
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Mar 8, 2003·Journal of Molecular and Cellular Cardiology·Sweder W E van de PollArnoud van der Laarse
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jun 5, 2003·Journal of Hypertension·UNKNOWN European Society of Hypertension-European Society of Cardiology Guidelines Committee
Sep 27, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·R P MasonT H Hintze
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
May 25, 2005·Archives of Internal Medicine·Richard H ChapmanJ Sanford Schwartz
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Dec 21, 2005·Medical Care·Michael L JohnsonRebecca J Beyth
Dec 22, 2005·American Heart Journal·Sonali P KulkarniEric D Peterson
Jan 13, 2006·The Journal of Clinical Hypertension·Domenic A Sica
Mar 1, 2006·Current Drug Targets. Cardiovascular & Haematological Disorders·R Preston Mason
Jul 11, 2006·The American Journal of Cardiology·Nathan D WongG Rhys Williams
Aug 10, 2006·The Journal of Clinical Hypertension·Franz H MesserliUNKNOWN AVALON Investigators
Aug 22, 2006·Journal of Clinical Pharmacology·Menger ChungCandace Bramson
Sep 22, 2006·Journal of Clinical Pharmacology·Menger ChungCandace Bramson
Dec 6, 2006·European Heart Journal·Peter SeverUNKNOWN ASCOT Steering Committee Members
Aug 7, 2007·The American Journal of Medicine·Sripal BangaloreFranz H Messerli
Sep 21, 2007·Atherosclerosis·Ian GrahamUNKNOWN ESC Committee for Practice Guidelines

❮ Previous
Next ❯

Citations

May 17, 2012·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Feb 28, 2013·Journal of Clinical Pharmacy and Therapeutics·Zorica CvetkovićAleksandar Nešković
Sep 26, 2017·Current Medical Research and Opinion·Louise E BartlettElizabeth E Roughead
Jan 7, 2014·Journal of Pharmacological Sciences·Tomio OkamuraTakeshi Imamura
Jun 4, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michel E BertrandJean-Jacques Mourad
Jan 1, 2013·Journal of Drug Assessment·Niki KatsikiAsterios Karagiannis
Nov 5, 2019·Journal of the Neurological Sciences·Johanna Andrea Gutiérrez-Vargas, Gloria Patricia Cardona-Gómez
Feb 27, 2021·Journal of Cardiovascular Medicine·Pasquale Perrone-FilardiDavide Cafiero
Apr 30, 2021·Pharmaceutical Biology·Guiying ZhangWenli Yin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

© 2021 Meta ULC. All rights reserved